	US 12,227,772 B2
	Modified sterol acyltransferases
Christopher Mark Farrell, Columbia, MD (US); Lisa Ann Laprade, Columbia, MD (US); Otto Martin Lehmann, Kaiseraugst (CH); and Joshua Trueheart, Columbia, MD (US)
Assigned to DSM IP ASSETS B.V., Heerlen (NL)
Appl. No. 17/050,603
Filed by DSM IP ASSETS B.V., Heerlen (NL)
PCT Filed May 21, 2019, PCT No. PCT/EP2019/063076 § 371(c)(1), (2) Date Oct. 26, 2020, PCT Pub. No. WO2019/224187, PCT Pub. Date Nov. 28, 2019.
Claims priority of application No. 627/18 (CH), filed on May 22, 2018.
Prior Publication US 2021/0115412 A1, Apr. 22, 2021
Int. Cl. C12N 9/10 (2006.01); C12P 33/00 (2006.01)

CPC C12N 9/1029 (2013.01) [C12P 33/00 (2013.01); C12Y 203/01026 (2013.01)]

10 Claims

1. A process for production of 7-dehydrocholesterol (7-DHC) comprising enzymatically converting acetyl-CoA into a sterol mix comprising zymosterol and 7-DHC with a host cell, wherein the percentage of 7-DHC in the sterol mix is at least 70%, and wherein the host cell is a recombinant host cell that expresses a modified enzyme selected from EC 2.3.1.26 having sterol acyltransferase activity comprising one or two amino acid substitutions at positions corresponding to residues 592 and 595 in the polypeptide according to SEQ ID NO:1, wherein the substituted amino acid corresponding to residue 592 in the polypeptide according to SEQ ID NO:1 is leucine and the substituted amino acid corresponding to residue 595 in the polypeptide according to SEQ ID NO:1 is aspartic acid.